MedPal AI (MPAL)  has reported its strongest month of pharmacy activity since launch, with more than 42,250 prescription items dispensed in May 2026. The performance exceeded the previous monthly record of 41,000 items and reflects continued growth in patient demand across the company's NHS and private pharmacy services.

The milestone takes MedPal's cumulative dispensing volume to more than 250,000 prescription items since launch. The company said the achievement demonstrates accelerating adoption of its technology-enabled pharmacy platform, while highlighting significant remaining capacity within its operations to support further growth.

MedPal noted that pharmacy gross margins exceeded 34% during the six months to 28 February 2026, as reported in its interim results. The company said the improvement reflects the operational leverage generated by its automated dispensing model as volumes continue to scale.

Based on May's dispensing performance, MedPal's pharmacy operations are now running at an annualised turnover rate of more than £5 million.

MedPal AI's Founder and Chief Executive Officer Jason Drummond said: "May was our best month yet, with over 42,250 items dispensed, and we have now passed a quarter of a million prescriptions since we began. To reach this scale in such a short period is a powerful validation of our automated, technology-led model - which, as our interim results showed, is delivering pharmacy gross margins of over 34% as we grow. We have built this momentum from a standing start, and with significant capacity still available across our dispensing operations, the Board sees a clear runway for continued, profitable growth."

View from Vox

MedPal's latest operational update highlights continued momentum in its pharmacy business, with record dispensing volumes translating into a growing revenue run rate and improving margins. With substantial capacity still available and demand continuing to increase, the company appears well positioned to scale its technology-led healthcare platform further while maintaining profitability.